Creatine HCl for elderly

Our research team is excited to announce the start of a new study (CONCRET-SARCOPA) which explores whether a specialized form of creatine (creatine hydrochloride) can improve muscle health, mobility, and cognitive performance in older adults living with sarcopenia, a condition characterized by age-related loss of muscle mass and function. Over a 12-week period, participants will receive either creatine HCl or placebo, and we will evaluate changes in body composition, muscle strength and mobility, brain performance, blood biomarkers related to metabolic and cellular health, and creatine levels within body tissues to better understand individual responsiveness to supplementation.

This work matters because sarcopenia significantly contributes to frailty, falls, reduced independence, and diminished quality of life in aging populations. Although creatine is widely recognized as a promising nutrient for supporting muscular and cellular energy, its effects in older adults with clinically defined sarcopenia remain under-studied. Our study aims to address this gap through a rigorous, carefully controlled research design.

What sets this study apart is its use of creatine HCl, a highly soluble form of creatine, combined with comprehensive assessments spanning muscle, mobility, cognitive function, metabolic biomarkers, and tissue creatine biology. By integrating these measures, we hope to determine whether creatine HCl can serve as part of a safe and effective strategy to help older adults preserve strength, mobility, cognitive function, and overall health.

We look forward to sharing updates as the study progresses. The trial is registered at ClinicalTrials.gov, and we are grateful to Vireo Systems Inc. for providing the creatine used in this research. As creatine science continues to advance, we are proud to contribute new evidence to this rapidly evolving field.